A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease

Trial Profile

A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Fimasartan (Primary)
  • Indications Coronary disorders
  • Focus Therapeutic Use
  • Acronyms FIMA-DEFER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Nov 2015 Planned End Date changed from 1 Jun 2013 to 1 May 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top